PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Changes in Registrant’s Certifying Accountant
Item4.01
|
Changes in Registrants Certifying Accountant. |
(a) Dismissal of Independent Registered Public Accounting Firm
On March23, 2017, Puma Biotechnology, Inc. (the Company) notified
PKF, LLP (formerly PKF, Certified Public Accountants, A
Professional Corporation) (PKF) of its dismissal as the Companys
independent registered public accounting firm effective
immediately. The dismissal of PKF was approved by the Audit
Committee of the Board of Directors of the Company (the Audit
Committee).
The audit reports of PKF on the Companys financial statements for
each of the fiscal years ended December31, 2016 and 2015 did not
contain an adverse opinion or a disclaimer of opinion, nor was
qualified or modified as to uncertainty, audit scope or
accounting principles.
During the fiscal years ended December31, 2016 and 2015, and the
subsequent interim period through March23, 2017, there were no
disagreements (as defined in Item304(a)(1)(iv) of Regulation S-K
and the related instructions to that Item) with PKF on any matter
of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreement,
if not resolved to the satisfaction of PKF, would have caused PKF
to make reference to the subject matter of the disagreement in
connection with its report.
During the fiscal years ended December31, 2016 and 2015, and the
subsequent interim period through March23, 2017, there was no
reportable event (as that term is defined in 304(a)(1)(v) of
Regulation S-K).
The Company provided PKF with a copy of this Current Report on
Form 8-K prior to its filing with the U.S. Securities and
Exchange Commission (the Commission) and requested PKF to furnish
the Company with a letter addressed to the Commission stating
whether PKF agrees with the statements contained herein. A copy
of PKFs letter dated March24, 2017 is attached as Exhibit 16.1 to
this Current Report on Form 8-K.
(b) Engagement of Independent Registered Public Accounting Firm
On March23, 2017, the Audit Committee engaged KPMG LLP (KPMG) as
the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017.
During the fiscal years ended December31, 2016 and 2015, and the
subsequent interim period through March23, 2017, neither the
Company nor anyone on its behalf consulted KPMG regarding (i)the
application of accounting principles to a specified transaction,
either completed or proposed, or the type of audit opinion that
might be rendered on the Companys financial statements, or
(ii)any matter that was either the subject of a disagreement or a
reportable event.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| 16.1 |
Letter of PKF, LLP (formerly PKF, Certified Public Accountants, A Professional Corporation) dated March24, 2017 |
About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Recent Trading Information
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) closed its last trading session down -0.40 at 39.70 with 501,211 shares trading hands.
